Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is the Wait Over? – Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX)

Page 1 of 2

The obesity industry is new on the stock block, but it has already become one of the most followed industries in our market. The two major competitors VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) have both received FDA approval for their drugs. Orexigen Therapeutics, Inc. (NASDAQ:OREX) is still trying to get approval for its obesity treatment Contrave. VIVUS, Inc. (NASDAQ:VVUS) has already launched its obesity pill Qsymia into the US market. The launch of Arena’s Belviq was initially delayed as the company had to wait for a DEA review of the abuse potential of Belviq. It has partnered with Eisai to launch the drug in America; while this reduces a lot of risk on the part of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), it reduces margins as well, as the company has to pay 33% from all wholesale collections to Eisai.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)In my recent articles on the obesity sector I have discussed the market potential of both drugs and compared both products as well. In my most recent article on Arena, I discussed the market impatience with the launch of Belviq. The market was expecting Arena to give a clear schedule for Belviq launch during its recent conference call. The company failed to live up to the Street’s expectations and did not give a clear guidance on Belviq launch. The stock slipped 6% on the news, but the company has already regained its pre-conference valuation.


Arena not only let investors down by not announcing concrete information on Belviq launch, but also missed the Street’s earnings expectations. The Street was expecting Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to post quarterly EPS of $-0.03, but the company missed expectations and posted earnings of $-0.10. This was the third time in the last four quarters that Arena has failed to live up to expectations. However, at this stage the earnings for the company are irrelevant as the stock is moving on Belviq news. Although the stock has recovered, the company will have to provide solid information on the drug launch.

European Approval

In more bad news for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors, the market is becoming more pessimistic on European approval of its obesity treatment. According to a couple of research firms, the chances of Belviq approval in Europe are now pretty slim. Needham and Oppenheimer have both suggested to their investors that the tough regulatory environment in Europe will likely result in rejection for Belviq. The competing drug Qsymia has already failed to receive approval in Europe due to potential cardiovascular risks that the drug might pose.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!